Key Points
-
The first patents of recombinant-DNA-derived biopharmaceuticals will expire in the near future, which should allow the marketing of 'generics'.
-
With classical drugs, generics can be marketed on the basis of limited documentation that shows physicochemical and pharmaceutical similarity to the innovator product.
-
Clinical data from a crossover volunteer study will generally suffice.
-
However, for biopharmaceuticals, which are in general large proteins, the biological and clinical properties cannot be completely predicted by current analytical methods, such as mass spectroscopy.
-
As illustrated by the problem of immunogenicity, the properties of a biopharmaceutical are dependent on many factors, which include downstream processing and formulation.
-
Even if the same genes are expressed in the same host cells, and identical production methods are used, this does not necessarily lead to a similar degree of immunogenicity.
-
Although the induction of antibodies is in many cases harmless, serious clinical consequences might occur, as shown by the current epidemic of the antibody-induced severe anaemia that is associated with the use of a specific form of recombinant erythropoietin.
-
So, the concept of generics cannot be extrapolated to biopharmaceuticals, and the term 'biogenerics' should not be used.
Abstract
The expiry of the first patents for recombinant-DNA-derived biopharmaceuticals will open the possibility of marketing generics, if they can be shown to be essentially similar to the innovator product. However, as shown by the problem of immunogenicity, the properties of biopharmaceuticals are dependent on many factors, including downstream processing and formulation. Products from different sources cannot be assumed to be bioequivalent, even if identical genes are expressed in the same host cells and similar production methods are used. Some of the influencing factors are still unknown, which makes it impossible to completely predict biological behaviour, such as immunogenicity, which can sometimes lead to serious side effects.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Chance, R. E., Root, M. A. & Galloway, J. A. The immunogenicity of insulin preparations. Acta Endocrinol. Suppl. 205, 185–198 (1976).
Milner, R. D. G. & Fiodh, H. (eds) Immunological Aspects of Human Growth Hormone: Proceedings of a Workshop, London, 12 November 1985. (Medical Education Services, Oxford, 1986).These papers give a comprehensive review of the immunogenicity of pituitary-derived and early-recombinant-DNA-derived human growth hormones.
Jacquemin, M. G. & Saint-Remy, J. M. Factor VIII immunogenicity. Haemophilia 4, 552–557 (1998).
Dietrich, F. M., Fischer, J. A. & Bijvoet, O. L. Formation of antibodies to synthetic human calcitonin during treatment of Paget's disease. Acta Endocrinol. 92, 468–476 (1979).
Schernthaner, G. Immunogenicity and allergenic potential of animal and human insulins. Diabetes Care 16, 155–165 (1993).
Rosenschein, U., Lenz, R., Radnay, J., Ben Tovim, T. & Rozenszajn, L. A. Streptokinase immunogenicity in thrombolytic therapy for acute myocardial infarction. Isr. J. Med. Sci. 27, 541–545 (1991).
Vanderschueren, S. M., Stassen, J. M. & Collen, D. On the immunogenicity of recombinant staphylokinase in patients and in animal models. Thromb. Haemost. 72, 297–301 (1994).
Chaffee, S. et al. IgG antibody response to polyethylene glycol-modified adenosine deaminase in patients with adenosine deaminase deficiency. J. Clin. Invest. 89, 1643–1651 (1992).
Grauer, A., Frank-Raue, K., Schroth, J., Raue, F. & Ziegler, R. Neutralizing antibodies against salmon calcitonin. The cause of a treatment failure in Paget's disease. Dtsch. Med. Wochenschr. 119, 507–510 (1994).
Gilles, J. G., Jacquemin, M. G. & Saint-Remy, J. M. Factor VIII inhibitors. Thromb. Haemost. 78, 641–646 (1997).
Frasier, S. D. Human pituitary growth hormone (hGH) therapy in growth hormone deficiency. Endocr. Rev. 4, 155–170 (1983).
Dummer, R. et al. Formation of neutralizing antibodies against natural interferon-β, but not against recombinant interferon-γ during adjuvant therapy for high-risk malignant melanoma patients. Cancer 67, 2300–2304 (1991).
Prabhakar, S. S. & Muhlfelder, T. Antibodies to recombinant human erythropoietin causing pure red cell aplasia. Clin. Nephrology 47, 331–335 (1997).
Oberg, K. et al. Treatment of malignant carcinoid tumors with recombinant interferon-α2B: development of neutralizing interferon antibodies and possible loss of antitumor activity. J. Natl Cancer Inst. 81, 531–535 (1989).One of the first studies to show the inhibition of efficacy by antibodies that are induced by human IFN-α.
Zang, Y. C. et al. Immunoregulation and blocking antibodies induced by interferon-β treatment in MS. Neurology 55, 397–404 (2000).
Kontsek, P., Liptakova, H. & Kontsekova, E. Immunogenicity of interferon-α2 in therapy: structural and physiological aspects. Acta Virol. 43, 63–70 (1999).
Melian, E. B. & Plosker, G. L. Interferon αcon-1: a review of its pharmacology and therapeutic efficacy in the treatment of chronic hepatitis C. Drugs 61, 1661–1691 (2001).
Girard, F. & Gourmelen, M. Clinical experience with somatonorm. Acta Pœdiatr. Scand. 325, 29–32 (1986).
Gribben, J. G. et al. Development of antibodies to unprotected glycosylation sites on recombinant human GM-CSF. Lancet 335, 434–437 (1990).
Karpusas, M. et al. The structure of human interferon-β: implications for activity. Cell. Mol. Life Sci. 54, 1203–1216 (1998).
MacDougall, I. C. Novel erythropoiesis stimulating protein. Semin. Nephrology 20, 375–381 (2000).
Antonelli, G. et al. Interferon antibodies in patients with infectious diseases. Biotherapy 10, 7–14 (1997).
Prümmer, O. Treatment-induced antibodies to interleukin-2. Biotherapy 10, 15–24 (1997).
Stubbe, P. in Growth Hormone Deficiency. Proceedings of a Workshop in Tubingen, 1981 (eds Ranke, M. B. & Bierich, J. R.) 92–99 (Urban and Schwarzenberg, Munich, 1983).
Fierlbeck, G. et al. Neutralizing interferon-β antibodies in melanoma patients treated with recombinant and natural interferon-β. Cancer Immunol. Immunother. 39, 263–268 (1994).
Hochuli, E. Interferon immunogenicity: technical evaluation of interferon-α2A. J. Int. Cytokine Res. 17, S15–S21 (1997).The first study to link the immunogenicity of human IFN-α2A to the presence of oxidized proteins.
Moore, W. V. & Leppert, P. Role of aggregated human growth hormone (hGH) in development of antibodies to hGH. J. Clin. Endocrinol. Metab. 51, 691–697 (1980).
Ryff, J.-C. Clinical investigation of the immunogenicity of interferon-α2A. J. Int. Cytokine Res. 17, S29–S33 (1997).
Rosendaal, F. R. et al. A sudden increase in factor VIII inhibitor development in multitransfused hemophilia A patients in the Netherlands. Blood 81, 2180–2186 (1993).This study shows the induction of immunogenicity by the introduction of a pasteurization step during production.
Cleland, J. L., Powell, M. F. & Shire, S. J. The development of stable protein formulations: a close look at protein aggregation, deamidation, and oxidation. Crit. Rev. Ther. Drug Carrier Syst. 10, 307–377 (1993).
Palleroni, A. V. et al. Interferon immunogenicity: preclinical evaluation of interferon-α2A. J. Int. Cytokine Res. 17, S23–S27 (1997).
Perini, P. et al. Interferon-β (IFN-β) antibodies in interferon-β1A- and interferon-β1B-treated multiple sclerosis patients. Prevalence, kinetics, cross-reactivity, and factors enhancing interferon-β immunogenicity in vivo. Eur. Cytokine Netw. 12, 56–61 (2001).
Kirchner, H. et al. Subcutaneous interleukin-2 and interferon-α2B in patients with metastatic renal cell cancer: the German outpatient experience. Mol. Biother. 2, 145–154 (1990).
Levy, F., Muff, R., Dotti-Sigrist, S., Dambacher, M. A. & Fischer, J. A. Formation of neutralizing antibodies during intranasal synthetic salmon calcitonin treatment of Paget's disease. J. Clin. Endocrinol. Metab. 67, 541–545 (1988).
Eisenberg, J. D. et al. Safety of repeated intermittent courses of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis. J. Pediatr. 131, 118–124 (1997).
Ross, C. et al. Immunogenicity of interferon-β in multiple sclerosis patients: influence of preparation, dosage, dose frequency, and route of administration. Danish Multiple Sclerosis Study Group. Ann. Neurol. 48, 706–712 (2000).
Antonelli, G. In vivo development of antibodies to interferon: an update to 1996. J. Int. Cytokine Res. 17, S39–S46 (1997).
Prescott, R. et al. The inhibitor antibody response is more complex in hemophilia A patients than in most nonhemophiliacs with factor VIII autoantibodies. Blood 89, 3663–3671 (1997).
Fakharzadeh, S. S. & Kazazian, H. H. Jr. Correlation between factor VIII genotype and inhibitor development in hemophilia A. Semin. Thromb. Hemost. 26, 167–171 (2000).
Schernthaner, G. et al. Immunogenicity of human insulin (Novo) or pork monocomponent insulin in HLA-DR-typed insulin-dependent diabetic individuals. Diabetes Care 6, 43–48 (1983).
Jeandidier, N. et al. Immunogenicity of intraperitoneal insulin infusion using programmable implantable devices. Diabetologia 38, 577–584 (1995).
Schellekens, H., Ryff, J.-C. & van der Meide, P. H. Assays for antibodies to human interferon-α: the need for standardisation. J. Int. Cytokine Res. 17, 5–8 (1997).
Casadevall, N. et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N. Engl. J. Med. 346, 469–475 (2002).An excellent clinical study, which shows the severe clinical consequences of the immunogenicity of a protein drug.
Wang, B. S. et al. Augmentation of hormonal activities with antibodies from cattle immunized with a combination of synthetic and recombinant growth hormone peptide. Anim. Biotechnol. 9, 21–33 (1998).
Zipkin, I. Amgen lays MGDF to rest. BioCentury [online] (cited 29 Apr 02) 〈http://www.biocentury.com/〉 (1998).
Chan, S. H. et al. Engineering of a mini-trichosanthin that has lower antigenicity by deleting its C-terminal amino acid residues. Biochem. Biophys. Res. Commun. 270, 279–285 (2000).
Collen, D. et al. Recombinant staphylokinase variants with altered immunoreactivity. I. Construction and characterization. Circulation 94, 197–206 (1996).
Chang, T. Y. Towards a quantitative model of immunogenicity: counting pathways in sequence space. J. Theor. Biol. 206, 255–278 (2000).
Van Regenmortel, M. H. Analysing structure–function relationships with biosensors. Cell. Mol. Life Sci. 58, 794–800 (2001).
Vanderschueren, S. M., Stassen, J. M. & Collen, D. On the immunogenicity of recombinant staphylokinase in patients and in animal models. Thromb. Haemost. 72, 297–301 (1994).
Collen, D., De Cock, F. & Stassen, J. M. Comparative immunogenicity and thrombolytic properties toward arterial and venous thrombi of streptokinase and recombinant staphylokinase in baboons. Circulation 87, 996–1006 (1993).
Dempster, A. M. Nonclinical safety evaluation of biotechnologically derived pharmaceuticals. Biotechnol. Annu. Rev. 5, 221–258 (2000).
Randolph, J. F., Stokol, T., Scarlett, J. M. & MacLeod, J. N. Comparison of biological activity and safety of recombinant canine erythropoietin with that of recombinant human erythropoietin in clinically normal dogs. Am. J. Vet. Res. 60, 636–642 (1999).
Zwickl, C. M. et al. Comparison of the immunogenicity of recombinant and pituitary human growth hormone in rhesus monkeys. Fundam. Appl. Toxicol. 16, 275–287 (1991).
Wierda, D., Smith, H. W. & Zwickl, C. M. Immunogenicity of biopharmaceuticals in laboratory animals. Toxicology 158, 71–74 (2001).
Ottesen, J. L. et al. The potential immunogenicity of human insulin and insulin analogues evaluated in a transgenic mouse model. Diabetologia 37, 1178–1185 (1994).
Stewart, T. A. et al. Transgenic mice as a model to test the immunogenicity of proteins altered by site-specific mutagenesis. Mol. Biol. Med. 6, 275–281 (1989).The first study to show the relevance of immunotolerant transgenic mice for predicting the immunogenicity of proteins in man.
Palleroni, A. V. et al. Interferon immunogenicity: preclinical evaluation of interferon-α2A. J. Int. Cytokine Res. 17, S23–S27 (1997).
Du, X. & Tang, J. G. Effects of deleting A19 tyrosine from insulin. Biochem. Mol. Biol. Int. 44, 507–513 (1998).
Steis, R. G. et al. Loss of interferon antibodies during prolonged continuous interferon-α2A therapy in hairy cell leukemia. Blood 77, 792–798 (1991).
Roffi, L. et al. Breakthrough during recombinant interferon-α therapy in patients with chronic hepatitis C virus infection: prevalence, etiology, and management. Hepatology 21, 645–649 (1995).
Schellekens, H. & Ryff, J.-C. Biogenerics; the Off-Patent Biotech Products. Trends Pharmacol. Sci. 23, 119–121 (2002).
Chaffee, S. et al. IgG antibody response to polyethylene glycol-modified adenosine deaminase in patients with adenosine deaminase deficiency. J. Clin. Invest. 89, 1643–1651 (1992).
Blumenfeld, Z., Frisch, L. & Conn, P. M. Gonadotropin-releasing hormone (GnRH) antibodies formation in hypogonadotropic azoospermic men treated with pulsatile GnRH-diagnosis and possible alternative treatment. Fertil. Steril. 50, 622–629 (1988).
Olsen, E. et al. Pivotal Phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J. Clin. Oncol. 19, 376–388 (2001).
Claustrat, B., David, L., Faure, A. & Francois, R. Development of anti-human chorionic gonadotropin antibodies in patients with hypogonadotropic hypogonadism. A study of four patients. J. Clin. Endocrinol. Metab. 57, 1041–1047 (1983).
Ragnhammar, P. & Wadhwa, M. Neutralising antibodies to granulocyte-macrophage colony stimulating factor(GM–CSF) in carcinoma patients following GM-CSF combination therapy. Med. Oncol. 13, 161–166 (1996).
Acknowledgements
I would like to thank P. Patten, K. Vahle, D. Crommelin, S. Goelz and S. Swanson for their critical comments. M. von Stein helped in preparing the manuscript. A generous educational grant by Maxygen Inc. enabled the writing of this review.
Author information
Authors and Affiliations
Related links
Related links
DATABASES
LocusLink
Medscape DrugInfo
LINK
Glossary
- RECOMBINANT DNA
-
The combination of DNA from different species; for example, the introduction of human genes into microorganisms.
- GENERIC
-
A copy of a drug that is introduced after the patent expires.
- BIOEQUIVALENCE
-
Similarity of biological properties.
- BIOPHARMACEUTICAL
-
A pharmaceutical product that consists of protein and/or nucleic acid.
- IMMUNOGENICITY
-
The capacity to elicit an immune response, such as the production of specific antibodies.
- EPITOPE
-
Part of a protein that is recognized by an antibody.
- SURFACE PLASMON RESONANCE
-
(SPR.) This occurs when surface plasmon waves are excited by light deflection at a metal–liquid interface. SPR can be used to investigate protein–protein interactions, such as antibody–antigen interactions.
- ADJUVANT
-
A substance that can boost the immune response.
- NEO-ANTIGEN
-
A non-self antigen that is new for an individual.
Rights and permissions
About this article
Cite this article
Schellekens, H. Bioequivalence and the immunogenicity of biopharmaceuticals. Nat Rev Drug Discov 1, 457–462 (2002). https://doi.org/10.1038/nrd818
Issue Date:
DOI: https://doi.org/10.1038/nrd818